Therapeutic potential and limitations of using hematopoietic stem cells as a treatment for patients with sickle cell anemia
Introduction: Hematopoietic stem cell transplantation (HSCT) is a promising therapy for sickle cell anemia, offering a potential cure. However, its access is limited by economic obstacles, such as high costs, shortage of compatible donors, and specialized infrastructure. The lack of financial resources in developing countries and the scarcity of public policies aggravate the situation.